Huang, Peirong
Narendran, Siddharth
Pereira, Felipe
Fukuda, Shinichi
Nagasaka, Yosuke
Apicella, Ivana
Yerramothu, Praveen
Marion, Kenneth M.
Cai, Xiaoyu
Sadda, Srinivas R.
Gelfand, Bradley D.
Ambati, Jayakrishna
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01EY028027)
Article History
Received: 30 June 2021
Accepted: 2 February 2022
First Online: 13 April 2022
Competing interests
: J.A. is a cofounder of iVeena Holdings, iVeena Delivery Systems and Inflammasome Therapeutics, and has been a consultant for Allergan, Boehringer-Ingelheim, Immunovant, Olix Pharmaceuticals, Retinal Solutions and Saksin LifeSciences unrelated to this work. S.R.S. has been a consultant for 4DMT, Abbvie/Allergan, Apellis, Amgen, Centervue, Heidelberg, Iveric, Novartis, Optos, Oxurion, Regeneron and Roche/Genentech, received speaker fees from Novartis, Nidek, Carl Zeiss Meditec and Optos, and received research instruments from Carl Zeiss Meditec, Nidek, Topcon, Centervue, Optos and Heidelberg unrelated to this work; J.A. and B.D.G. are cofounders of DiceRx. J.A., S.N., I.A., F.P. and B.D.G. are named as inventors on patent applications filed by their university.